Multiple Myeloma Program
We Are Different from Other Treatment Centers.
Our specialists have more than two decades of experience treating multiple myeloma. They have each treated more than 5,000 multiple myeloma patients.
The Multiple Myeloma Program at Holden Comprehensive Cancer Center — Iowa's only NCI-designated Comprehensive Cancer Center — is known for its tandem autologous transplant treatment, an approach offered at very few medical centers around the country. Research demonstrates that the median survival rate with this treatment process is 10 years or more and that 80% of newly diagnosed myeloma patients will achieve complete remission. No other treatment method for multiple myeloma has proven to be as effective in research studies.
“When I started treating myeloma, the median survival for patients was about 2 and a half years," Guido Tricot, MD, PhD says. "Today, we have aggressive and effective therapies available, like our tandem transplant protocol, that have increased the median survival to more than 10 years. My goal is to keep patients alive with the best quality of life possible until we find a cure.”
Multiple myeloma specialist Guido Tricot, MD, PhD, discusses new advances in treating multiple myeloma and why patients come to Iowa from all over the world to seek his new therapies. These advances allow patients to live 10 years or more with 80% percent of newly diagnosed patients achieving complete remission.
Tricot, MD, PhD also has extensive knowledge in treating and evaluating patients with myeloma-related conditions, like amyloidosis, MGUS, plasmacytomas, Waldenström's disease, and Castleman’s disease.
- Contact us for your questions or concerns about multiple myeloma.